Occult Hypercalcemia Unmasked: Insights From Remitting Seronegative Symmetrical Synovitis With Pitting Edema (RS3PE) Syndrome Associated With a Gastrointestinal Lymphoma

隐匿性高钙血症的揭示:来自伴有胃肠道淋巴瘤的缓解性血清阴性对称性滑膜炎伴凹陷性水肿(RS3PE)综合征的启示

阅读:1

Abstract

Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is a rare inflammatory arthritis that may present as a paraneoplastic syndrome. We report a case of a 51-year-old woman who initially responded to high-dose steroids for RS3PE but later developed persistent hypercalcemia. Serum calcium ranged from 3.03 to 4.02 mmol/L, with suppressed parathyroid hormone (PTH), suggesting a non-parathyroid cause. Despite initial suspicion of infection-related hypercalcemia, calcium levels remained elevated after antimicrobial therapy. The 25-hydroxyvitamin D level was elevated, although serum 1,25-dihydroxyvitamin D was not directly measured. Immunohistochemistry revealed strong expression of parathyroid hormone-related protein (PTHrP) and 25-hydroxyvitamin D3-1α-hydroxylase (CYP27B1), indicating potential contributions from both humoral and vitamin D-mediated pathways. The patient received supportive treatment with diuretics, calcitonin, and denosumab, which successfully corrected hypercalcemia. Gastrointestinal endoscopy and biopsy ultimately confirmed diffuse large B-cell lymphoma (DLBCL). She then underwent anti-lymphoma chemotherapy, resulting in sustained remission and stable calcium levels. This case highlights the diagnostic challenges of RS3PE with hypercalcemia and the importance of considering underlying malignancy when standard therapy fails. It also demonstrates that PET-CT may fail to detect tumors in hollow organs and that gastrointestinal endoscopy should be considered in unresolved cases. Early recognition of tumor-associated hypercalcemia and a mechanism-based diagnostic approach are essential for effective treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。